About Us
Homepage
/
Customer-centric and focus on quality

Core Values

All categories

News Center

Viwit’s Levetiracetam Tablets Approved by FDA 2024-04-09 11:28:41
On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.
Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA 2024-01-26 11:09:29
On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.
Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA 2023-12-22 13:19:44
Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.
Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA 2023-12-19 11:25:05
On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).
Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA 2023-12-07 08:31:28
On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA 2023-10-31 15:33:57
On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.

Customer-centric and focus on quality

Customer-centric and focus on quality

  • Categories:Core Values
  • Time of issue:2020-06-01 00:00:00
  • Views:0
Description:
Description:
Information

All business activities of the company are centered on the customers. We continue to pay attention and listen to the needs of the customers, and to offer better products and services.

In a pharmaceutical industry, product quality is the foundation and lifeline of a company. Viwit believes strongly in the quality of products that we make. We would not be offering any products to the public that we would not give to our own families and loved ones. Viwit believes in making life easier, more convenient, and more secure.

 

Scan the QR code to read on your phone

search
Confirm
Close
About Us
Company Introduction Corporate History Business Introduction Corporate Governance Company Culture Corporate Honors Viwit Family Media Center Video
R&D and Innovation
R&D Innovation Product Pipeline Achievements
Products
Drug Products Biologics APIs Intermediates Boranes
Innovation
CDMO Project Collaboration In-/Out-Licensing Joint Venture
Sustainable
EHS Energy Quality Supplier
News Center
In 2024 In 2023 In 2022 In 2021 In 2020 In 2019 In 2018 In 2017 In 2016
Join Us
Talent Philosophy Talent Development Salary and Benefits Campus Recruiting Social Recruitment
Contact Us
Online Message Contact Us
News Center
dp EN
dp 中文

wz

wz